Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J, Rodriguez E, Maitland ML, Tsai FY, Socinski MA, Berlin JD, Thomas JS, Al Baghdadi T, Wang IM, Guo C, Golmakani M, Clark LN, Gazdoiu M, Li M, Tolcher AW. Rodon J, et al. Among authors: socinski ma. ESMO Open. 2024 Apr;9(4):102961. doi: 10.1016/j.esmoop.2024.102961. Epub 2024 Apr 18. ESMO Open. 2024. PMID: 38640748 Free PMC article. Clinical Trial.
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2.
Shaverdashvili K, Reyes V, Wang H, Mehta D, Marsh C, Waas JK, VanderWeele RA, Peracha SM, Liang H, Socinski MA, Gerber DE, Dowell JE, Villaruz LC. Shaverdashvili K, et al. Among authors: socinski ma. EClinicalMedicine. 2023 Nov 21;66:102317. doi: 10.1016/j.eclinm.2023.102317. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192592 Free PMC article.
Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Bruno R, Marchand M, Yoshida K, Chan P, Li H, Zou W, Mercier F, Chanu P, Wu B, Lee A, Li C, Jin JY, Maitland ML, Reck M, Socinski MA. Bruno R, et al. Among authors: socinski ma. Clin Cancer Res. 2023 Oct 13;29(20):4314. doi: 10.1158/1078-0432.CCR-23-2525. Clin Cancer Res. 2023. PMID: 37828897 No abstract available.
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer.
Owen JS, Rackley RJ, Hummel MA, Roepcke S, Huang H, Liu M, Idris TA, Murugesan SMN, Marwah A, Loganathan S, Ranganna G, Barve A, Waller CF, Socinski MA. Owen JS, et al. Among authors: socinski ma. Eur J Drug Metab Pharmacokinet. 2023 Nov;48(6):675-689. doi: 10.1007/s13318-023-00855-3. Epub 2023 Oct 4. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37792130 Clinical Trial.
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Pellini B, Madison RW, Childress MA, Miller ST, Gjoerup O, Cheng J, Huang RSP, Krainock M, Gupta P, Zou W, Shames DS, Moshkevich S, Ballinger M, Liu MC, Young A, Srivastava MK, Oxnard GR, Socinski MA. Pellini B, et al. Among authors: socinski ma. Clin Cancer Res. 2023 Nov 14;29(22):4596-4605. doi: 10.1158/1078-0432.CCR-23-1578. Clin Cancer Res. 2023. PMID: 37702716 Free PMC article.
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
Nagasaka M, Brazel D, Baca Y, Xiu J, Al-Hallak MN, Kim C, Nieva J, Swensen JJ, Spetzler D, Korn WM, Socinski MA, Raez LE, Halmos B, Ou SI. Nagasaka M, et al. Among authors: socinski ma. Transl Oncol. 2023 Oct;36:101744. doi: 10.1016/j.tranon.2023.101744. Epub 2023 Jul 27. Transl Oncol. 2023. PMID: 37516008 Free PMC article.
330 results